Top

Published in:

01-02-2020 | Cardiomyopathy | Case Report

Implantation of a HeartMate 3 in a 13-Year-Old Child with Dilated Cardiomyopathy

Authors: Raymond Pfister, Matthias Kirsch, Julia Natterer, Stefano Di Bernardo, Rene Pretre

Published in: Pediatric Cardiology | Issue 2/2020

Abstract

Left ventricular assist device is a well-established therapy in heart failure adults, but less in children. A 13-year-old-boy with severe left ventricular dysfunction did not improve under medical treatment. A HeartMate 3 (HM3) was implanted as a bridge to transplantation. Despite the size limitation, the HM3 shows promising results and our case supports its feasibility in children.

Available only for authorised users

Potapov EV, Stiller B, Hetzer R (2007) Ventricular assist devices in children: current achievements and future perspectives. Pediatr Transplant 11:241–255CrossRef

Miera O, Potapov EV, Redlin M, Stepanenko A, Berger F, Hetzer R et al (2011) First experiences with the HeartWare ventricular assist system in children. Ann Thorac Surg 91:1256–1260CrossRef

Krabatsch T, Netuka I, Schmitto JD, Zimpfer D, Garbade J, Rao V et al (2017) Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure: 1 year results from the CE mark trial. J Cardiothorac Surg 4:12

Fraser CD Jr, Jaquiss RD, Rosenthal DN, Humpl T, Canter CE, Blackstone EH et al (2012) Prospective trial of a pediatric ventricular assist device. N Engl J Med 367:532–541CrossRef

Cabrera AG, Sundareswaran KS, Samayoa AX, Jeewa A, McKenzie ED, Rossano JW et al (2013) Outcomes of pediatric patients supported by the HeartMate II left ventricular assist device in the United States. J Heart Lung Transplant 32:1107–1113CrossRef

Burki S, Adachi I (2017) Pediatric ventricular assist devices: current challenges and future prospects. Vasc Health Risk Manag 13:177–185CrossRef

Chivukula VK, Beckman JA, Prisco AR, Dardas T, Lin S, Smith JW et al (2019) Left ventricular assist device inflow cannula angle and thrombosis risk. ASAIO J 65:152–159CrossRef

Title: Implantation of a HeartMate 3 in a 13-Year-Old Child with Dilated Cardiomyopathy
Authors: Raymond Pfister
Matthias Kirsch
Julia Natterer
Stefano Di Bernardo
Rene Pretre
Publication date: 01-02-2020
Publisher: Springer US
Keywords: Cardiomyopathy
Implantable Cardioverter Defibrillator
Heart Failure
Published in: Pediatric Cardiology / Issue 2/2020
Print ISSN: 0172-0643
Electronic ISSN: 1432-1971
DOI: https://doi.org/10.1007/s00246-019-02229-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Implantation of a HeartMate 3 in a 13-Year-Old Child with Dilated Cardiomyopathy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Pediatric Myocarditis Protocol: An Algorithm for Early Identification and Management with Retrospective Analysis for Validation

Clinical Significance of Central Venous Pressure During Exercise After Fontan Procedure

Clinical Profile and Long-Term Follow-Up of Children with Brugada Syndrome

Does Repeated Measurement of a 6-Min Walk Test Contribute to Risk Prediction in Children with Dilated Cardiomyopathy?

Risk Factors and Predictors of Cardiac Erosion Discovered from 12 Japanese Patients Who Developed Erosion After Atrial Septal Defect Closure Using Amplatzer Septal Occluder

Invasive Cardiac Procedures in Interstage Single Ventricle Patients in Emergent Hospitalizations

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page